ARYx Therapeutics, focuses on discovering and developing product candidates designed to eliminate known safety issues associated with commercially successful drugs, filed for an IPO Thursday with the SEC. The firm filed to be listed on the NASDAQ under the ticker "ARYX." Morgan Stanley is the lead manager on the deal. No terms were disclosed in the initial filing.
